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Abstract A variant of transforming growth factor-j? type II receptor (TGF-BRII) cDNA was isolated from a mouse brain cDNA library. The 
predicted receptor is identical to previously reported mouse TGF$RII except that the isofonn has an insertion sequence of 25 amino acids in the 
predicted ligand-binding domain. By the use of reverse transcription-polymerase chain reaction (RT-PCR), transcripts for both isoforms were detected 
in all tissues and developing embryos examined. The isofotm transiently expressed in COS cells showed a similar ligand-binding specificity to authentic 
TGF-flI1. These results suggest hat the mouse TGF-/JR11 gene generates multiple isoforms, possibly by alternative splicing, as reported for activin 
type IIB receptor; and an isoform which has the extra sequence in the ligand-binding domain is also involved in the TGF-/3 signal transduction. 
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1. Iutrodution 
Transforming growth factor-Z3 (TGF-B) is a family of pol- 
ypeptide growth factors the members of which are involved in 
the regulation of cell growth and differentiation [1,2]. There are 
three subtypes of TGF-/I, namely TGF-Bl, $2 and -83, which 
are closely related to one another in primary structure and their 
transcripts have been detected in a wide variety of vertebrate 
tissues and cultured cell lines. The biological effects of TGF-/Is 
are mediated by interaction between the ligand and specific 
TGF-b receptors, which have been studied mostly with TGF- 
pl. Three types of receptors with distinct molecular weights 
were identified in a variety of tissues by affinity cross-linking 
experiments using LZSI-labeled TGF-/I1 , which are designated as 
type I, II and III receptors [3]. The type III receptor with the 
largest molecular weight ranging from 200 to 300 kDa, has been 
characterized as a proteoglycan and does not appear to be 
involved in intracellular signaling [4,5]. Conversely, type I and 
type II receptors, which show molecular weights of 53 and 75 
kDa, respectively, play a central role in TGF-/3 signaling. It was 
reported that the type II receptor can bind TGF-pl by itself but 
requires the type I receptor for signal transduction. In contrast, 
the type I receptor requires the type II receptor for both signal 
transduction and ligand binding [6]. Recently, cDNAs that 
encode type I and II receptors have been cloned and found to 
encode serine-threonine kinases in their cytoplasmic domain 
[7]. The mouse TGF-/I type II receptor (TGF-BRII) cDNA has 
previously been reported to encode a 567 amino acid membrane 
protein with a 159 amino acid extracellular domain, and a high 
level of transcript was detected in a variety of tissues except 
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brain [8]. Here we report the isolation of an isoform of TGF- 
j?RII cDNA from a mouse brain cDNA library. The isoform 
encodes the TGF-/.I type II receptor with a 25 amino acid 
insertion sequence in the extracellular domain which retains the 
capacity to bind TGF-/Il. 
2. Materials and methods 
2. I. Cloning of mouse TGF-BRII, cDNA 
Deeenerate olieonucleotides (5’-TATT/C)ATGGC(~CC- 
(T/C/;i/c)GA(AZGjGT-3’ and 5’(A/GjTC(A/G)TG(AZG)TCCCA- 
(A/G)CA(T/C)TC-3’) were designed based on conserved kinase subdo- 
main sequences (domains VIII and XI) and used as primers for reverse 
transcription-polymerase chain reaction (RT-PCR) to isolate cDNAs 
encoding serine-threonine kinase receptors from an osteoblastic ell 
line, MC3T3-El. The PCR fragments were s&cloned into T-over- 
hanged BlueScriptIIKS(-) and sequenced. The PCR fragment that 
contains the putative coding region with similarity to human TGF-/I 
type II receptor was used to screen a mouse brain cDNA library. Five 
positive clones were isolated from 1 x lo6 plaques. The longest cDNA 
(3.8 kb) was subcloned into BlueScriptIIKS(-) and sequenced with a 
BcaBEST dideoxy sequencing kit (TAKARA Biochemicals). 
2.2. Detection of mouse TGF-PRII mRNAs 
Total RNA was prepared from mouse adult tissues and embryos 
using the acid guanidinium thiocyanate-phenol/chloroform extraction 
method [9]. For PCR analysis, cDNA was synthesized from 500 ng 
aliquots of total RNA as described previously [lo]. Samples, which 
contained 5 ml of the cDNA solution, were cycled 30 times at 94’C for 
1 min, 60°C for 1 min, 72°C for 2 min according to the manufacturer’s 
instruction (Perkin-Elemer Cetus). The amplified products were sepa- 
rated on an 1.5% agarose gel and stained with ethidium bromide. 
Primers used for the PCR analysis were 5’-TGTGGACGCGCA- 
TCGCCAGC-3’ (nucleotide position 202-221, for 5’) and 5’-ACAC- 
GGTAGCAGTAGAAGAT-3’ (nucleotide position 783-802, for 3’). 
2.3. Cell culture and affinity cross-linking 
COS cell culture and afBnity cross-linking were carried out using 
?-labeled TGF-/31 as previously described [ll]. ‘ZSI-Labeled recombi- 
nant human TGF;Bl was purchased from Du Pont Inc. Recombinant 
human TGF;Bl and TGF-/32 were purchased from Austral Biologicals. 
3. Results aad discussion 
In an attempt to isolate new members of receptor serine- 
threonine kinase receptors, oligonucleotide primers designed in 
subdomain VIII and XI were used to amplify cDNA synthe- 
sized from MC3T3-El cells mRNA [12]. Several cDNA frag- 
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CCGGGGGCCTCCTCCGGGCCTCCGAU;TCCGGGGATCGCC~ TCTGGCCCGCATCCTGAGAGGGCGAGGAGTAAAGGCGCAGCCC 
GGGGTCCCCGAGGCTCGGTTCGTGGCGCACCA~CGGTCTATGA- CGGGGGCTGCCATGGGTCGCTGCTCCGGGGCC 
ttt MGRGLLRGL 
TOTGGCCGCTGCATATCGTCCPGTGULCGCGCATCGCCAG 
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CGGTCUGCTTCCACAGCT -TGCGATGTGAGAC~~ CCAGAAGTCCTGCATGAGCAA-GCATCA 
VKLPQL@KF@DVRLST@DNQKS@MS 
CCAAGCPCACCTACCAUXCTTCA CTCTGGAAGATGCCGCTT T CCAAGTGTGTC GAGACTTTCT 
KLTYHGFTLEDAASPK@VM KEKKRAGETFF 
TCATGTGTGCCTGTAACATGGAA GTGCAACGATTACATCATC mTCGGAAGAATACACCACCTCCCGACCTGTTOlTG 
M@A@NME EON DYIIFSEEYTTSSPDLLLVI 
TTATCCAAGTGACGGGTGTCAGCCTCCTGCCTCCGCTGGG 
IQVTGVSLLPPLGIAIAVIIIFYCYRVHRQ 
GCTCCGAczJmxxTCCACGTGCGC CARCAACATCAACCACRACACGGAGCTGCTGCCCATCGAG 
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GCTTCGCCGAGOTCTACAAGGCCAAGCn;AAGCAGRACAC CCTACGAGGAGT 1080 
FAEVY KAKL KQ_N T BEQ F ETVAVK I F P YE E Y 309 
ACTCCTCGTGGAAAACAGAGAA GGRCATCTTCTCCGATATCAACCTUULGCATGAGAACATC~~~~T~~C~~~ 1170 
S SWKT EKD I F S D I NL KH EN I LQ FLTAE E RK 339 
AGACAGAGCTGGGCAAGCAGTACXGCTGATCACGGCGTTCCACGCGAAGGGCAACCT GCAGGAGTACCTCACGAGGCATGTCATCAGCT 1260 
TE LGKQ YWL I TAFHAKGNLQEYLT RHVI SW 369 
GGGAGGACCTULGGAAGCK;GGCAGCTCCCTGGCCCGGGG CCAAGATGC 1350 
ED L RKLGS SLARG I AHLH SD HTP CGRP KMP 399 
CCATPOfiCAWLGGGACCTCAAGAGCTCTAACRTCCTAGTWC 1440 
IVHRDL KS SN I LVKNDLTCC LCDF GLS LRL 429 
TGGACCCTACTCTGTCTGTGGATGACCTGGCCAACAGCGG 1530 
DP TL SVDDLAN SGQVGTARYMAP EVLE S RM459 
TGAATCTGGAAAACGTGGAGTCGTTCAAGCAGACGGATGTCTACTCCATGGCTCTGGTACT CT G AATGACGTCCCGCTGCAATGCTG 1620 
NL ENVES FKQTDVY SMALVLWEMT S RCNAV489 
TGGGAGAAGTGRPIGGATTACGRGCCCCCATTTGGTTCCA GTGCTGAGAG 1710 
GEVKD Y EP P FG S KVRE H PCVESMKD SVLRD 519 
AXGAGGGCGGCCGGAAATTCC~CACCAGGGCATCCAGATCGTGTGTGAGACTTTGAC~CCATG 1800 
RGRP E I P S FWLNHQGIQ IVCET LT ECWDHD 549 
ACCCC-GTCTTGT GGCRWLGCGCTTCAGTGAGCTGC9GCATCC~~~~CT~~T~CCC 1890 
P EARLTAQCVAERF S ELEHP ERL SGRSC SO 579 
AGGAGAAGATTCCAGAAGATGGCTCGCTGAACACTACCAAATAGCTTTTTCTGGGCA GGCTGGGCCAAGCCTCCAGAAGCCGTCCTCTAG 1980 
E K I P ED G S LNT T K SMP 592 
Fig. 1. Nucleotide and deduced amino acid sequence of mTFR17-7 (mTGF-BRII3 cDNA. The upstream in-frame stop codon is indicated by asterisks. 
The signal peptide and the transmembrane domain are indicated by single underline. Potential N-linked glycosylation sites are indicated by double 
underline. An insertion sequence of25 amino acids is shaded. Cysteine residues conserved in the extracellular domain are circled. The ends of the 
intracellular kinase domain are indicated by arrows. 
merits which encode serine-threonine kinase sequences were tide and deduced amino acid sequences of the mTFR17-7 
isolated and then each used to screen a mouse brain cDNA cDNA. The major structural difference between mTFR17-7 
library. Finally, one of the clones, designated as mTFR17-7, receptor and the mTGF#RII (which we designated as mTGF- 
was found to be very similar yet distinct from a previously /SRI& and mTGF-/?RII,, respectively) is that the mTFR17-7 
reported mouse TGF$RII cDNA [8]. Fig. 1 shows the nucleo- receptor has a 25 amino acid insertion sequence in the extracel- 
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lular domain (shaded in Fig. 1: urthermore, the sequence 
contains a potential N-linked glycosylation site and a cysteine 
residue, suggesting that the mTGF$RII, may have different 
ligand-binding specificity and biological function from those of 
mTGF#RII, . Comparison of the cDNA sequences of mTGF- 
flIIl and mTGF#RII, at the nucleotide level revealed that a 
75 nucleotide sequence was inserted at a codon which encodes 
Va13* of mTGF$RII,, and the insertion generates one amino 
acid change (va13* to Phe5’ of mTGF-j?RIIz) in addition to the 
25 amino acid insertion (Fig. 2). There are some minor differ- 
ences between the two isoforms at the nucleotide level, but these 
are thought to be due to the diversity of the mouse strains. 
Therefore, it is most likely that these type II receptor isoforms 
are generated by the differential splicing of mRNA that is 
transcribed from the originally identical TGF-/l type II receptor 
gene, as previously reported for mouse activin type IIB receptor 
gene [13]. 
In order to examine expression levels of the two distinct 
forms of the mTGF+?RII in various tissues and developing 
embryos, RT-PCR was performed using synthetic oligonucleo- 
tide primers that discriminate between the two isoforms. In this 
assay, a set of primers, which were designed so as to cover the 
insertion site and amplified products corresponding to the 
isoforms, show different mobility on an agarose gel (mTGF- 
/?RIIl for 526 bp and mTGF-j?RII, for 601 bp in Fig. 3A). As 
shown in Fig. 3B and C, both RNA species were detected in 
all tissues and embryos examined; this suggests that mTGF- 
jIRI12 may act as a signaling receptor for TGF-B in these tissues 
and embryos because we have reported that the TGF-fi type I 
receptor also co-expressed in these sites and the type I receptor 
could form a functional receptor complex with mTGF$RII, 
([8,11], and unpublished observations). Although Lawler et al. 
has shown that mTGF-/?RII1 was rarely expressed in brain [8], 
both forms of mTGF#RII were detected in brain at a signifi- 
cant level under our experimental conditions. This discrepancy 
may be due to the improved sensitivity of RT-PCR. 
A line of evidence suggests that a specific receptor for TGF- 
82 exists in mammals but the TGF$RII, isolated from mouse 
and human could not bind efficiently to TGF-B2 [8,14]. More- 
over, TGF-@2 protein is more abundant in brain from which 
mTGF$RII, cDNA was isolated [15]. Therefore, it was ex- 
pected that the insertion of 25 amino acid might alter the ligand 
specificity of the mTGF$RII and make the receptor as for 
TGF#2. This possibility was examined by an affinity cross- 
linking experiment using 1251-labeled TGF-pl. In Fig. 4, tran- 
siently expressed mTGF-j?RII, in COS cells bound [1251]TGF- 
j?l and formed an affinity-labeled complex of 95 kDa under 
non-reducing condition. After subtracting the molecular weight 
25 a. 8. 
mTGF43R’h LEC 
mTGF43RIIi AAGTCGGTTAACAGTGAT KS@NSD 
Fig. 2. Generation of mouse TGF-,9 type II receptor isofonns. The 
cDNA and translated amino acid sequences near possible alternative 
splicing site are shown. An insertion sequence of 25 amino acids is 
shaded. Amino acids that change as a result of the splicing are circled. 
mTGF43Rlh (526 bp) 
mTGF43Rlk (601 bp) A 
bp 
Fig. 3. Expression of mouse TGF#I type II receptor isoforms in adult 
tissues and embryos. (A) Primer positions used for RT-PCR. Schematic 
structure of mouse TGF;B type II receptor is represented by a box. 
Black boxes represent the signal sequence (SG) and the transmembrane 
(TM) domain. An insertion sequence (INS) within the extracellular 
domain is represented by a shaded box. The intracellular serine-threon- 
ine kinase domain is represented by a hatched box. Forward (F) and 
reverse (R) primers are indicated by arrows. The amplified products of 
526 bp and 601 bp are expected for mTGF-/IRE, and mTGF-BRII,, 
respectively. (B and C) Detection of transcripts for mTGF$RII 
isoforms in adult tissues and developing embryos. Total RNA (500 ng) 
purified from adult tissues (B) and embryos (C) were subjected to 
RT-PCR (see section 2). Positions of PCR products for mTGF-/IRII, 
and mTGF-/IRE, are indicated as II, and II,, respectively. 
of the cross-linked [1251]TGF-B1 (25 kDa), this band corre- 
sponds to a protein of 70 kDa. The binding was effectively 
replaced by an excess amount of unlabeled TGF;Bl but not by 
that of TGF-/?2. The human TGF-BRII, expressed in COS cells 
also shows specific binding to TGF-/?I , as previously reported. 
Control cells transfected with an expression vector alone exhib- 
ited no cross-linked products. These results indicate that the 
mTGF-/JRII, has similar ligand-binding specificity to the TGF- 
WI,. 
In this paper, we identified a new isoform of mTGF-j?IUI 
which has an insertion sequence in the extraccllular domain. 
22 A. Suzuki et al. IFEBS Letters 355 (1994) 19-22 
Fig. 4. Affinity cross-linking of mTGF$?RII,. COS cells transfected 
with the indicated expression plasmids were incubated with [“‘BTGF- 
/Jl and subjected to chemical cross-linking. The positions of type II and 
type III receptors are indicated on the right of the figure. Ligand 
binding specificity of the receptors was examined by the use of TGF;Bl 
or -82 as competitor. 
Although the receptor was isolated from adult brain which 
produces TGF-fi2 preferentially, the receptor displayed effec- 
tive binding of TGF-Bl but not TGF-62: the regular function 
of the mTGF$RII, is not yet clear. However, the insertion of 
an extra 25 amino acids into the mTGF-/?RII may alter the 
cell’s response to TGF-j?l because Glansbeek et al. reported 
that a molecular weight shift of the type II receptor expressed 
in bovine articular chondrocytes is linked to change of the cell 
response to TGF-Bl [16J. The biological function of the new 
isoform of TGF-jYRI1 will be investigated in future studies. 
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